Matthew R. Janes, Ph.D.
Affiliations: | 2010 | Biological Sciences - Ph.D. | University of California, Irvine, Irvine, CA |
Area:
Molecular BiologyGoogle:
"Matthew Janes"Parents
Sign in to add mentor| David A. Fruman | grad student | 2010 | UC Irvine | |
| (The role of the phosphoinositide 3-kinase (PI3k)-target of rapamycin (TOR) pathway in leukemia and as a therapeutic target in hematologic malignancies.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Gilardi M, Wang Z, Proietto M, et al. (2020) Tipifarnib as a Precision Therapy for HRAS-Mutant Head and Neck Squamous Cell Carcinomas. Molecular Cancer Therapeutics |
| Molina-Arcas M, Moore C, Rana S, et al. (2019) Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer. Science Translational Medicine. 11 |
| Gualberto A, Scholz C, Mishra V, et al. (2019) Abstract CT191: Mechanism of action of the farnesyltransferase inhibitor, tipifarnib, and its clinical applications Cancer Research. 79 |
| Witzig T, Sokol L, Kim W, et al. (2019) TIPIFARNIB IN RELAPSED OR REFRACTORY ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA (AITL) AND CXCL12+ PERIPHERAL T-CELL LYMPHOMA (PTCL): PRELIMINARY RESULTS FROM A PHASE 2 STUDY Hematological Oncology. 37: 64-65 |
| Misale S, Fatherree JP, Cortez E, et al. (2018) KRAS G12C NSCLC models are sensitive to direct targeting of KRAS in combination with PI3K inhibition. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Hansen R, Firdaus SJ, Li S, et al. (2018) An Internally Controlled Quantitative Target Occupancy Assay for Covalent Inhibitors. Scientific Reports. 8: 14312 |
| Hansen R, Peters U, Babbar A, et al. (2018) The reactivity-driven biochemical mechanism of covalent KRAS inhibitors. Nature Structural & Molecular Biology |
| Janes MR, Zhang J, Li LS, et al. (2018) Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor. Cell. 172: 578-589.e17 |
| Gualberto A, Scholz C, Mishra V, et al. (2018) Crosstalk between the IGF1 and CXCL12 Pathways Defines Objective Responses to the Farnesyl Transferase Inhibitor Tipifarnib in AML and PTCL Patients Blood. 132: 5349-5349 |
| Li L, Janes MR, Zhang J, et al. (2018) Abstract 929: Discovery of novel covalent KRASG12C inhibitors that display high potency and selectivity in vitro and in vivo Cancer Research. 78: 929-929 |